Home
  >  
Section 37
  >  
Chapter 36,176

Evaluation of immunogenicity and protective efficacy against Mycobacterium tuberculosis infection elicited by recombinant Mycobacterium bovis BCG expressing human Interleukin-12p7 and Early Secretory Antigen Target-6 fusion protein

2011

DOI: 10.1111/j.1348-0421.2011.00376.x
Accession: 036175050
Download citation:  
Text
  |  
BibTeX
  |  
RIS
Early Secretory Antigen Target-6 (ESAT-6) protein of Mycobacterium tuberculosis is absent in Mycobacterium bovis Bacillus Calmette-Gu rin (BCG) and Mycobacterium microti and has been demonstrated to stimulate strong cell-mediated immunity. Interleukin-12 (IL-12) can play crucial roles in regulating IFN-? production and Th1 effectors production. In this study, we constructed three recombinant BCG (rBCG) vaccines that could express proteins of human IL-12p7 and/or ESAT-6 and evaluated their immunogenicity and protective efficacy in mice. Our experiments illustrated that the rBCG-IE (expressing a fusion protein of human IL-12p7 and ESAT-6) was capable of inducing stronger Th1 type cell-mediated immune responses than conventional BCG, or rBCG-I (expressing human IL-12p7), or rBCG-E (expressing ESAT-6). However, the results of protective experiments showed that rBCG-IE could only confer similar and even lower protective efficacy against M.tuberculosis H37Rv infection compared with BCG vaccine.

PDF emailed within 0-6 h: $19.90




Related References

Deng, Y.; Bao, L.; Yang, X. 2011: Evaluation of immunogenicity and protective efficacy against Mycobacterium tuberculosis infection elicited by recombinant Mycobacterium bovis BCG expressing human Interleukin-12p70 and Early Secretory Antigen Target-6 fusion protein Microbiology and Immunology 55(11): 798-808
Deng, Y.H.; He, H.Y.; Zhang, F.J. 2013: Immunogenicity and protective efficacy conferred by a novel recombinant Mycobacterium bovis bacillus Calmette-Guérin strain expressing interleukin-12p70 of human cytokine and Ag85A of Mycobacterium tuberculosis fusion protein Scandinavian Journal of Immunology 78(6): 497-506
Xu, Z.Zhong.; Chen, X.; Hu, T.; Meng, C.; Wang, X.Bo.; Rao, Y.; Zhang, X.Ming.; Yin, Y.Lan.; Pan, Z.Ming.; Jiao, X.An. 2016: Evaluation of Immunogenicity and Protective Efficacy Elicited by Mycobacterium bovis BCG Overexpressing Ag85A Protein against Mycobacterium tuberculosis Aerosol Infection Frontiers in Cellular and Infection Microbiology 6: 3
Bao, L.; Chen, W.; Zhang, H.; Wang, X. 2003: Virulence, immunogenicity, and protective efficacy of two recombinant Mycobacterium bovis bacillus Calmette-Guérin strains expressing the antigen ESAT-6 from Mycobacterium tuberculosis Infection and Immunity 71(4): 1656-1661
Tchilian, E. Z.; Desel, C.; Forbes, E. K.; Bandermann, S.; Sander, C. R.; Hill, A. V. S.; McShane, H.; Kaufmann, S. H. E. 2011: Immunogenicity and Protective Efficacy of Prime-Boost Regimens with Recombinant ureC hly+ Mycobacterium bovis BCG and Modified Vaccinia Virus Ankara Expressing M. tuberculosis Antigen 85A against Murine Tuberculosis Infection and Immunity 79(5): 2133-2133
Deng, Y.H.; Sun, Z.; Yang, X.L.; Bao, L. 2010: Improved immunogenicity of recombinant Mycobacterium bovis bacillus Calmette-Guérin strains expressing fusion protein Ag85A-ESAT-6 of Mycobacterium tuberculosis Scandinavian Journal of Immunology 72(4): 332-338
Yang, X.; Bao, L.; Deng, Y. 2011: A novel recombinant Mycobacterium bovis bacillus Calmette-Guerin strain expressing human granulocyte macrophage colony-stimulating factor and Mycobacterium tuberculosis early secretory antigenic target 6 complex augments Th1 immunity Acta Biochimica et Biophysica Sinica 43(7): 511-518
Tchilian, E.Z.; Desel, C.; Forbes, E.K.; Bandermann, S.; Sander, C.R.; Hill, A.V.S.; McShane, H.; Kaufmann, S.H.E. 2009: Immunogenicity and protective efficacy of prime-boost regimens with recombinant (delta)ureC hly+ Mycobacterium bovis BCG and modified vaccinia virus ankara expressing M. tuberculosis antigen 85A against murine tuberculosis Infection and Immunity 77(2): 622-631
Wang, L.-M.; Bai, Y.-L.; Shi, C.-H.; Gao, H.; Xue, Y.; Jiang, H.; Xu, Z.-K. 2008: Immunogenicity and protective efficacy of a DNA vaccine encoding the fusion protein of mycobacterium heat shock protein 65 (Hsp65) with human interleukin-2 against Mycobacterium tuberculosis in BALB/c mice Apmis: Acta Pathologica Microbiologica et Immunologica Scandinavica 116(12): 1071-1081
Deng, Y.-H.; He, H.-Y.; Zhang, B.-S. 2014: Evaluation of protective efficacy conferred by a recombinant Mycobacterium bovis BCG expressing a fusion protein of Ag85A-ESAT-6 Journal of Microbiology Immunology and Infection 47(1): 48-56
Asma Abdullah, N.U.R.U.L.; Mohd Nor, N.O.R.A.Z.M.I. 2011: Immunogenicity and in vitro protective efficacy of recombinant Mycobacterium bovis bacille Calmette Guerin (rBCG) expressing the 19 kDa merozoite surface protein-1 (MSP-119) antigen of Plasmodium falciparum Parasitology Research (1987) 108(4): 887-897
Nurul, A.A.; Norazmi, M.N. 2011: Immunogenicity and in vitro protective efficacy of recombinant Mycobacterium bovis bacille Calmette Guerin (rBCG) expressing the 19 kDa merozoite surface protein-1 (MSP-1(19)) antigen of Plasmodium falciparum Parasitology Research 108(4): 887-897
Li, Q.; Yu, H.; Zhang, Y.; Wang, B.; Jiang, W.; Da, Z.; Xian, Q.; Wang, Y.; Liu, X.; Zhu, B. 2011: Immunogenicity and protective efficacy of a fusion protein vaccine consisting of antigen Ag85B and HspX against Mycobacterium tuberculosis infection in mice Scandinavian Journal of Immunology 73(6): 568-576
Wang, J.; Qie, Y.; Liu, W.; Wang, H. 2012: Protective efficacy of a recombinant BCG secreting antigen 85B/Rv3425 fusion protein against Mycobacterium tuberculosis infection in mice Human Vaccines and Immunotherapeutics 8(12): 1869-1874
Horwitz, M.A.; Harth, G.ün.; Dillon, B.J.; Maslesa-Galic, S. 2005: Enhancing the protective efficacy of Mycobacterium bovis BCG vaccination against tuberculosis by boosting with the Mycobacterium tuberculosis major secretory protein Infection and Immunity 73(8): 4676-4683